Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

NBP Softgel Capsules

NO Ultra

NRT-S

Nab-paclitaxel

Naltrexone and 2-butanol

NanoDOX 1% doxycycline monohydrate Hydrogel

Neutral environment with radiation

New infant formula

Nicotinamide Riboside

Nicotine Replacement Therapy (Habitrol)

Nicotine Replacement therapy

Nicotine replacement therapy sampling

Nitazoxanide Tablets

Nitrate enriched beetroot juice

Nitroprusside Sodium

Non-invasive chromosome screening（NICS）

Normal Saline (Placebo)

Nutributter Program

Nutrient supplement to pregnant women (PNS)

Nutrition Intervention

Nutritional Supplement

Nutritional therapy

Obinutuzumab

Oleoylethanolamide (OEA)

Frequently asked questions